CGF-Induced Mitochondrial Dysfunction Suppresses Colorectal Cancer: Mechanistic Insights from Metabolic Reprogramming and Cell Cycle Arrest

Study Background and Research Question

Colorectal cancer (CRC) is one of the most prevalent and deadly malignancies worldwide, ranked as the third most common cancer and the second leading cause of cancer-related mortality. Despite advances in surgical and adjuvant therapies, recurrence and metastasis remain significant challenges, with up to 30% of patients experiencing disease relapse. The increasing incidence, fueled by aging populations and lifestyle factors, underscores the urgent need for more effective, targeted, and well-tolerated treatments. In this context, natural products have emerged as promising sources for novel anticancer agents due to their diverse bioactivity and unique mechanisms of action. Anthocyanins and polyphenols from purple sweet potato have previously demonstrated anti-tumor effects via autophagy induction, apoptosis, and inhibition of epithelial-mesenchymal transition. However, the specific components and their mechanisms remain incompletely understood. The central research question addressed by Jiang et al. (2026) is whether the natural compound Cya-Gly-Fer (CGF), extracted from purple sweet potato, can inhibit CRC progression, and, if so, by what molecular pathways.

Key Innovation from the Reference Study

The pivotal innovation described in Jiang et al. lies in the identification and mechanistic dissection of CGF, a previously uncharacterized anthocyanin derivative. Unlike prior studies that broadly attributed antitumor activity to purple sweet potato extracts, this work isolates CGF and systematically demonstrates its efficacy in CRC models. The authors reveal that CGF impairs CRC cell proliferation and metastasis by triggering a cascade of events: disruption of ATP-binding cassette (ABC) transporters, intracellular ATP accumulation, mitochondrial dysfunction, and excessive reactive oxygen species (ROS) generation. This metabolic stress ultimately suppresses the MAPK/ERK1/2/c-MYC signaling axis, resulting in cell cycle arrest and apoptosis. The study thus provides a comprehensive molecular framework linking metabolic reprogramming with cell fate determination in cancer cells exposed to a natural product.

Methods and Experimental Design Insights

To elucidate the antitumor mechanism of CGF, the authors employed a combination of in vitro, ex vivo, and in vivo models. Key experimental systems included established CRC cell lines, patient-derived organoids, and mouse xenograft models, allowing for robust cross-validation of findings. The workflow incorporated integrated transcriptomic and metabolomic profiling to characterize changes in gene expression and central carbon metabolism. Functional assays assessed mitochondrial integrity, ROS levels, and cellular ATP content. Cell cycle progression was monitored using flow cytometry, with propidium iodide (PI) staining to distinguish cell cycle phases G0/G1, S, and G2/M based on DNA content—a widely accepted approach in cell cycle progression analysis. Apoptosis was quantitatively evaluated, including detection of sub-G1 DNA content (a hallmark of apoptotic DNA fragmentation). The multi-modal design enabled precise mechanistic mapping from molecular perturbation to phenotypic outcome.

Protocol Parameters

• CGF treatment in vitro: CRC cell lines exposed to defined concentrations (e.g., 10–100 μM) for 24–72 hours to monitor mitochondrial function, ROS, and cell cycle effects.
• Patient-derived organoid exposure: Organoids cultured with CGF to assess growth inhibition and apoptosis under physiologically relevant conditions.
• Xenograft administration: Mice bearing CRC tumors received CGF via tail vein or oral gavage; tumor size and metastasis tracked over several weeks.
• Flow cytometry cell cycle assay: PI staining after RNase A treatment to remove RNA background; analysis of DNA content to resolve G0/G1, S, and G2/M phases and apoptosis by sub-G1 peak.
• Metabolomic profiling: LC-MS-based quantification of ATP and central carbon metabolites in treated vs. control samples.
• Transcriptomic analysis: RNA-seq to identify differentially expressed genes involved in ABC transport, metabolic pathways, and apoptosis/cell cycle regulation.

Core Findings and Why They Matter

The study's central findings can be summarized as follows:

• CGF suppresses CRC growth and metastasis in both cell-based and animal models, suggesting translational potential for novel therapy.
• Disruption of ABC transporters by CGF leads to intracellular ATP accumulation, setting off metabolic stress and mitochondrial dysfunction.
• Mitochondrial dysfunction results in excessive ROS production, which is known to damage cellular components and trigger cell death pathways.
• MAPK/ERK1/2/c-MYC axis inhibition is observed downstream of ROS accumulation, aligning with suppressed proliferation and increased apoptosis.
• Cell cycle analysis reveals arrest at specific checkpoints, predominantly in G0/G1 phase, with a significant sub-G1 population indicative of apoptosis—findings validated by flow cytometry and PI staining.
• Favorable safety and pharmacokinetics are demonstrated in animal models, supporting the feasibility of further preclinical development.

These mechanistic insights show that targeted disruption of mitochondrial and metabolic homeostasis is a viable strategy against CRC. The ability to induce both cell cycle arrest and apoptosis via ROS-dependent signaling distinguishes CGF from conventional cytotoxic agents, with potential to overcome resistance linked to metabolic adaptation in cancer cells.

Comparison with Existing Internal Articles

The cell cycle and apoptosis insights gleaned from Jiang et al. are directly relevant to researchers employing cell cycle progression analysis in cancer studies. Internal resources such as "Cell Cycle Assay Kit: Precision Analysis of G0/G1, S, G2/M Phases" and "Cell Cycle Assay Kit K2263: Precision in Epigenetic and Apoptosis Profiling" explain how PI-based flow cytometry enables high-resolution discrimination of cell cycle phases and detection of apoptosis by sub-G1 peak. The reference study reinforces the essential role of these techniques, showing that accurate measurement of DNA content and apoptotic events is critical when mapping the effects of metabolic stressors like CGF. These internal articles also discuss technical enhancements and troubleshooting strategies for the Cell Cycle Assay Kit (K2263), which can be directly applied to protocols similar to those used in the paper.

Moreover, the reference to epigenetic pathways in articles like "Panobinostat Targets Epigenetic Pathways in MLL-Rearranged ALL" underscores a broader theme in cancer research: that cell fate can be modulated not only by metabolic and signaling disruptions, as seen with CGF, but also by direct epigenetic intervention. Together, these resources form a toolkit for dissecting the complex interplay between metabolism, signaling, and the cell cycle in oncogenesis.

Limitations and Transferability

Despite its comprehensive design, the study has some limitations. First, while the efficacy and safety of CGF are well-demonstrated in preclinical models, human clinical data are lacking. The mechanisms identified—ROS-mediated mitochondrial dysfunction, ATP accumulation, and inhibition of MAPK/ERK/c-MYC—are robustly supported in CRC models but may not fully extrapolate to other cancer types due to tissue-specific metabolic wiring. Additionally, long-term effects and the potential for resistance development were not addressed. The specificity of CGF for cancer versus normal cells, although suggested by favorable safety in animals, requires further investigation. Finally, the reliance on PI staining and flow cytometry underscores the need for rigorous protocol optimization to ensure reproducibility across laboratories.

Research Support Resources

For researchers seeking to replicate or extend these experiments, precise measurement of cell cycle phases and apoptosis is essential. The Cell Cycle Assay Kit (Catalog No. K2263) (SKU K2263) from APExBIO provides a validated workflow for discriminating G0/G1, S, and G2/M phases, as well as apoptosis detection by sub-G1 peak using PI and RNase A treatment. This kit is suitable for flow cytometry-based assays that align with the methodologies employed by Jiang et al. in their study of CGF. Utilizing such standardized reagents can enhance data robustness when investigating metabolic reprogramming, mitochondrial function, and therapeutic efficacy in cancer research.